+86-0571-88373719 info@bartymedical.com
Categories
Contact Us

Address: (Linghao Road) No.2 Street, No.20 Economic Development Zone, Hangzhou

E-mail: info@bartymedical.com

Tel: +86-057188373719

Mobile:+86-15868837129

Drug Eluting Cardiac Stent

Drug Eluting Cardiac Stent

DRUG ELUTING CARDIAC STENT PRODUCT INTRODUCTION A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots......

Send Inquiry

DRUG ELUTING CARDIAC STENT
PRODUCT INTRODUCTION
A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombi), could otherwise block the stented artery, a process called restenosis. The stent is usually placed within the peripheral or coronary artery by an interventional cardiologist or interventional radiologist during an angioplasty procedure.

CLINICAL APPLICATION
CARDIAC DRUG ELUTING STENT in current clinical use were approved by the FDA after clinical trials showed they were statistically superior to bare-metal stents for the treatment of native coronary artery narrowings, having lower rates of major adverse cardiac events (usually defined as a composite clinical endpoint of death + myocardial infarction + repeat intervention because of restenosis).
Clinical trials have shown the benefits of coronary stenting with bare-metal stents over other methods of angioplasty, including balloon angioplasty and atherectomy. Drug-eluting stents (DES) have also been extensively studied, and are generally superior to bare-metal stents with respect to occurrence of major adverse cardiac events (MACE, generally defined as death, myocardial infarction, or the need for a repeat revascularization procedure). Stents are indicated to improve the diameter of the coronary artery lumen, when narrowing (generally because of atherosclerosis) causes ischemia (reduced oxygen delivery to the muscle supplied by that artery).

Main characteristics:
- Abluminal Coating
- Biodegradable polymer
- Paclitaxel Elution
- Moderate drug release profile (60% in 10 days and the remainder in 30 days)
- In 6 to 9 months the polymer is completely degraded
- Cobalt Chromium Platform
- High Flexibility
- Great side branch access

OUR COMPANY PROFILE
Established: Aug, 2015
Add: Economical and Development area, Hangzhou, Zhejiang
Registered Capital: 3 Million US Dollar
Product: specialized in cardiovascular and Peripheral Vessel currently .

System Certification
Passed ISO 13485 quality management system certification approved by TUV-SUD in October, 2016; ISO 13485 quality management system certification approved by BS in July, 2017. FDA applying.